Next Article in Journal
Impact of Influenza A Virus Infection on Growth and Metabolism of Suspension MDCK Cells Using a Dynamic Model
Next Article in Special Issue
Branched-Chain Amino Acid Deprivation Decreases Lipid Oxidation and Lipogenesis in C2C12 Myotubes
Previous Article in Journal
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Previous Article in Special Issue
Abnormal Iron and Lipid Metabolism Mediated Ferroptosis in Kidney Diseases and Its Therapeutic Potential
 
 
Review

Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy

Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA
Academic Editor: Silvia Sacchi
Metabolites 2022, 12(3), 240; https://doi.org/10.3390/metabo12030240
Received: 24 February 2022 / Revised: 6 March 2022 / Accepted: 9 March 2022 / Published: 11 March 2022
(This article belongs to the Special Issue Amino Acid Metabolism in Health and Disease)
Coronavirus disease 2019 (COVID-19) represents a major public health crisis that has caused the death of nearly six million people worldwide. Emerging data have identified a deficiency of circulating arginine in patients with COVID-19. Arginine is a semi-essential amino acid that serves as key regulator of immune and vascular cell function. Arginine is metabolized by nitric oxide (NO) synthase to NO which plays a pivotal role in host defense and vascular health, whereas the catabolism of arginine by arginase to ornithine contributes to immune suppression and vascular disease. Notably, arginase activity is upregulated in COVID-19 patients in a disease-dependent fashion, favoring the production of ornithine and its metabolites from arginine over the synthesis of NO. This rewiring of arginine metabolism in COVID-19 promotes immune and endothelial cell dysfunction, vascular smooth muscle cell proliferation and migration, inflammation, vasoconstriction, thrombosis, and arterial thickening, fibrosis, and stiffening, which can lead to vascular occlusion, muti-organ failure, and death. Strategies that restore the plasma concentration of arginine, inhibit arginase activity, and/or enhance the bioavailability and potency of NO represent promising therapeutic approaches that may preserve immune function and prevent the development of severe vascular disease in patients with COVID-19. View Full-Text
Keywords: COVID-19; arginine; arginase; nitric oxide synthase; immunopathology; endothelial dysfunction; thrombosis; vascular disease COVID-19; arginine; arginase; nitric oxide synthase; immunopathology; endothelial dysfunction; thrombosis; vascular disease
Show Figures

Graphical abstract

MDPI and ACS Style

Durante, W. Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy. Metabolites 2022, 12, 240. https://doi.org/10.3390/metabo12030240

AMA Style

Durante W. Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy. Metabolites. 2022; 12(3):240. https://doi.org/10.3390/metabo12030240

Chicago/Turabian Style

Durante, William. 2022. "Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy" Metabolites 12, no. 3: 240. https://doi.org/10.3390/metabo12030240

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop